Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101580 · ClinicalTrials.gov registry record · Phase 1
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
A Phase 1 study of Advanced Pancreatic Cancer, sponsored by Polaris Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02101580 is a Phase 1 study of Advanced Pancreatic Cancer that has completed, run by Polaris Group. The registered enrollment target is 21 participants, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02101580, a Phase 1 study of Advanced Pancreatic Cancer, has completed, sponsored by Polaris Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
Conditions Studied
Interventions
- DRUG ADI-PEG 20
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101580
The ClinicalTrials.gov registry entry for NCT02101580 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT02101580 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02101580 about?
NCT02101580 is a clinical study titled "Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer". Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
What is the current status of trial NCT02101580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2014-11-17. Estimated completion is 2017-10-06.
What conditions does trial NCT02101580 study?
This clinical trial studies the following conditions: Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT02101580?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT02101580?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02101580 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.